ProfileGDS5678 / 1417051_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 27% 27% 26% 27% 28% 27% 27% 26% 27% 27% 27% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6755928
GSM967853U87-EV human glioblastoma xenograft - Control 22.6279127
GSM967854U87-EV human glioblastoma xenograft - Control 32.6280427
GSM967855U87-EV human glioblastoma xenograft - Control 42.5590326
GSM967856U87-EV human glioblastoma xenograft - Control 52.5720527
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7217828
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6682627
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6031627
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5841926
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6119827
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.614127
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.597427
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6244527
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6211527